Q2 2026 Autolus Therapeutics PLC Earnings Call Transcript

Aug 11, 2026 / 12:30 PM GMT

Release Date Price: €1.78

Transcript 10-Q8-K

Key Points

Positve

Strong Q2 2026 revenue growth: net product revenue of $45.7 million, up from $26.2 million in Q1, with first-half revenue of $71.9 million nearly matching full-year 2025.
Raised full-year 2026 revenue guidance to $140-$150 million from $120-$135 million, reflecting strong commercial momentum.
Gross margin improved significantly to 55% in Q2 from 6% in Q1, driven by higher production volumes, operational efficiencies, and cost reductions.
Expanded commercial footprint to over 80 authorized treatment centers in the U.S. (exceeding year-end target) and approaching 20 in the U.K., with plans to reach 90+ U.S. centers by year-end.
Positive real-world data from the ROCA Consortium presented at Tandem meeting, supporting product adoption and physician interest.
Secured a $250 million strategic financing with Perceptive Advisors, providing capital runway into Q2 2028 and supporting pipeline development.
Pipeline progress: multiple upcoming data catalysts, including Carlisle study update at ACR, FELIX analyses, Auto-8 initial data, and Bobcat study in progressive MS.
Manufacturing capacity well-positioned for ALL market, with clinical production initiated at Nucleus facility, improving cost per batch economics.
Strong physician adoption and repeat usage at established centers, with expansion of CAR-T users and referral support.
U.K. launch showing strong initial adoption, with market access expanding to Scotland, providing additional growth potential.

Negative

Revenue guidance implies a potential slight decline in Q3 or Q4 from Q2's $45.7 million, reflecting seasonality and conservatism.
U.K. contribution remains minor relative to U.S., with sales substantially less than 10% of U.S. revenue, indicating early-stage launch.
SG&A expenses increased to $41.2 million in Q2 from $30.3 million in Q2 2025, driven by commercialization costs and one-time restructuring charges.
Net loss of $39.1 million in Q2, though improved from $47.9 million in Q2 2025, indicates ongoing profitability challenges.
Gross margin target of 65%-70% for the ALL business is not expected for 12-18 months, with current margin at 55%.
Dependence on a limited number of high-volume centers for revenue, with adoption still concentrated among certain physicians.
Potential seasonality in sales could lead to quarterly fluctuations, as seen in Q2's surge driven by Tandem data.
Pipeline data readouts are several quarters away, with key catalysts like Bobcat MS data not expected until 2027.
Competitive differentiation in light chain amyloidosis (Auto-8) may be challenging due to high response rates expected in the indication.
Cash runway into Q2 2028 relies on achieving revenue milestones for additional financing tranches, adding uncertainty.

Refinitiv StreetEvents Event Transcript
E D I T E D V E R S I O N

AUTL.OQ - Autolus Therapeutics PLC
Q2 2026 Autolus Therapeutics PLC Earnings Call
Aug 11, 2026 / 12:30PM GMT

=====================
Presentation
--------------------------------------------------------------------------------
Unidentified_1 [1]
--------------------------------------------------------------------------------
Good day, and thank you for standing by. Welcome to the Autoloss Therapeutics Second Quarter 2026 Financial Results Conference Call. At this time, all participants are in a listen-only mode. After the speaker's presentation, there will be a question-and-answer session. To ask a question during the session, you will need to press *11 on your telephone. You will then hear an automated message advising your hand is raised. To withdraw your question, please press *11 again. Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Executive Director of Investor Relations, Amanda Cray. Please go ahead.

----------------------------------------------

Already have an account? Log in

Get the full story

Subscribe Now

	Access to All Earning Calls and Stock Analysis
	30-Year Financial on one screen
	All-in-one Stock Screener with unlimited filters
	Customizable Stock Dashboard
	Real Time Insider Trading Transactions
	8,000+ Institutional investors’ 13F holdings
	Powerful Excel Add-in and Google sheets Add-on
	All data downloadable
	Quick customer support
	And much more...

7-Day Free Trial · Cancel Anytime

Subscription fee may be tax deductible.

Excellent

4.6 out of 5

Trustpilot

Research Tools

All-In-One Screener Stock Ideas Stock List Guru List Guru Real-Time Picks Insider List Insider Trades Economic Indicators Sector & Industry Performance DCF Calculator Calculators Discussion Board

Product

Pricing Plans Excel Add-In Google Sheets Add-on Data API Stock Comparison Table Manual of Stocks Instant Alerts Mobile App Newsletters Signup 中文

Education

Financial Glossary Tutorials FAQ Buffett Indicator Shiller P/E Yield Curve Today U.S. Inflation Rate Global Market Valuation Fed Net Liquidity Buffett Assets Allocation

Company

About GuruFocus Career Contact Us Advertise Term of Use Privacy Policy Referral Program Partner Program

Survey

We'd love to learn more about your experiences on GuruFocus.com and how we can improve!

Take Survey

Disclaimers

GuruFocus.com is not operated by a broker or a dealer. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes are provided by QuoteMedia, Inc. (CSI). Company fundamental data is provided by Morningstar. Analyst estimates data is sourced from both Refinitiv and Morningstar, with priority given to Refinitiv data. Data is updated daily.